B1791089: An Open-Label, Multicenter Study To Evaluate The Pharmacokinetics of Single And Multiple Intravenous Doses Of Pantoprazole In Two Age Cohorts Of Hospitalized Pediatric Subjects 1 To 16 Years Of Age Who Are Candidates For Acid Suppression Therapy
Study of Drug in Patients 1-16 Years of Age with Gastroesophageal Reflux Disease (GERD)
Sponsor: Pfizer
Enrolling: Male and Female Patients
IRB Number: AAAR4382
U.S. Govt. ID: NCT02401035
Contact: Joseph Picoraro, MD: 212-305-5903 / jp3386@cumc.columbia.edu
Additional Study Information: The purpose of this study is to characterize the pharmacokinetics (PK) and safety of intravenous (IV) pantoprazole in patients 1 to 16 years old who are candidates for acid suppression therapy.
This study is closed
Investigator
Joseph Picoraro, MD
Do You Qualify?
Is your child between 1 and 16 years of age? Yes No
Is your child expected to be hospitalized due to illness for at least 7 days? Yes No
s your child a candidate for acid suppression therapy (ie, GERD, suspected GERD, symptomatic GERD, endoscopically proven GERD)? Yes No
Submit
Cancel
You may be eligible for this study

Place Holder



Cancel
For more information, please contact:
Joseph Picoraro, MD
jp3386@cumc.columbia.edu
212-305-5903
This website uses cookies as well as similar tools and technologies to understand visitors’ experiences. By continuing to use this website, you consent to Columbia University’s usage of cookies and similar technologies, in accordance with the Columbia University Website Cookie Notice.
I AGREE